imipenem, anhydrous has been researched along with Ventilator-Associated Pneumonia in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (30.00) | 29.6817 |
| 2010's | 26 (65.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Alarcón, T; Girón, RM; Gómez-Punter, RM; Ibáñez, A | 1 |
| Jarčuška, P; Porubčin, Š; Rovňáková, A; Zahornacký, O | 1 |
| Ha, DT; Ho-Le, TP; Hoang, HQ; Nguyen, DA; Nguyen, TA; Nguyen, TSM; Nguyen, TV; Pham, TTN; Tran, GM; Tran, NV; Tran-Nguyen, CH | 1 |
| Ebaed, MED; Gad, GF; Hussein, AK; Ibrahim, MM; Sarhan, HA; Tammam, TF | 1 |
| Aubry, A; Bréchot, N; Brossier, F; Jarlier, V; Lu, Q; Luyt, CE; Micaëlo, M; Monsel, A | 1 |
| Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Wongpoowarak, W | 1 |
| Aubry, A; Bréchot, N; Brisson, H; Brossier, F; Chastre, J; Combes, A; Jarlier, V; Lu, Q; Luyt, CE; Micaelo, M; Rouby, JJ; Trouillet, JL | 1 |
| Chen, CL; Chiu, CH; Huang, CW; Lee, HY; Wu, SR | 1 |
| Armand-Lefevre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M | 1 |
| Galani, I; Giamarellos-Bourboulis, EJ; Pistiki, A; Safarika, A | 1 |
| Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M | 1 |
| Baccouche, N; Bahloul, M; Bouaziz, M; Chaari, A; Chtara, K; Hammami, A; Medhioub, F; Mnif, B; Pham, T | 1 |
| Bai, KJ; Hsieh, TC; Hsu, CW; Jean, SS; Lam, C; Lee, WS | 1 |
| Akalın, H; Heper, Y; İşçimen, R; Kahveci, F; Kelebek, N; Ocakoğlu, G; Özvatan, T; Sınırtaş, M; Yılmaz, E | 1 |
| Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP | 1 |
| Chaudhury, A; Kalawat, U; Rani, AS; Sumant, S; Venkataramana, B; Verma, A | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Jaruratanasirikul, S; Sudsai, T | 1 |
| Restrepo, MI | 1 |
| Amin, A | 1 |
| Akhras, K; DeLong, K; Ingham, M; McGarry, LJ; Merchant, S; Nathwani, D; Pawar, V; Thompson, D; Weinstein, MC | 1 |
| Aydemir, S; Bacakoğlu, F; Taşbakan, MS; Yamazhan, T | 1 |
| Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Chen, J; Mody, SH; Shorr, AF; Zilberberg, MD | 1 |
| Chen, J; Mody, SH; Ramsey, AM; Shorr, AF; Zilberberg, MD | 1 |
| Cox, JC; Drachman, DA; Hibbard, ML; Kopelman, TR; Maly, TJ; Matthews, MR; O'Neill, PJ; Quan, AN; Vail, SJ | 1 |
| Chuang, YC; Cooper, CA; Dartois, N; Datsenko, O; Dukart, G; Dzyublik, O; Freire, AT; Gandjini, H; Glumcher, F; Kim, MJ; Korth-Bradley, JM; Maroko, RT; Melnyk, V | 1 |
| Furtado, GH; Gales, AC; Medeiros, EA; Perdiz, LB; Santos, AF | 1 |
| Chastre, J; Cirillo, I; Clavel, M; Kaniga, K; Kimko, H; Kollef, MH; Michiels, B; Redman, R; Restrepo, MI | 1 |
| Martin-Loeches, I; Torres, A | 1 |
| Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S | 1 |
| Archontoulis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Mega, A; Pavleas, I; Rigas, K; Thomopoulos, G; Vernikos, P | 1 |
| Bahloul, M; Bouaziz, M; Chaari, A; Chelly, H; Dammak, H; Hakim, A; Hamida, CB; Hergafi, L; Kallel, H; Rekik, N | 1 |
| Jaganath, A; Kumari, HB; Radhakrishnan, M; Rao, GS | 1 |
| Chastre, J; Friedland, I; Kaniga, K; Lee, M; Prokocimer, P; Wunderink, R | 1 |
| Gilbert, D | 1 |
| Brunin, G; Decamps, F; Dewavrin, F; Di Pompeo, C; Durocher, A; Favory, R; Jozefowicz, E; Mathieu, D; Nseir, S | 1 |
| Friedland, I; Gast, C; Ingham, M; Ketter, N; Lee, M; Merchant, S; Nathwani, D; Quintana, A | 1 |
2 review(s) available for imipenem, anhydrous and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Imipenem; Patient Acuity; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2022 |
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Imipenem; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
12 trial(s) available for imipenem, anhydrous and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Pharmacodynamics of imipenem in critically ill patients with ventilator-associated pneumonia.
Topics: Adult; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imipenem; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Respiration, Artificial; Treatment Outcome | 2013 |
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Thienamycins | 2014 |
Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Models, Statistical; Monte Carlo Method; Pneumonia, Ventilator-Associated; Prospective Studies | 2014 |
Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Plasma; Pneumonia, Ventilator-Associated | 2009 |
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Double-Blind Method; Drug Combinations; Hospital Mortality; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Pneumonia; Pneumonia, Ventilator-Associated; Tigecycline; Treatment Outcome | 2010 |
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Doripenem; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2012 |
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome | 2006 |
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Endotoxemia; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis | 2006 |
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Topics: Aged; Anti-Bacterial Agents; APACHE; Carbapenems; Doripenem; Female; Hospital Mortality; Humans; Imipenem; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Treatment Outcome | 2008 |
"The truth, if it exists, is in the details".
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Pneumonia, Ventilator-Associated; Severity of Illness Index; Treatment Outcome | 2008 |
Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Bronchitis; Female; Hospital Mortality; Humans; Imipenem; Intensive Care Units; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiration, Artificial; Time Factors; Tracheitis | 2008 |
Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Costs and Cost Analysis; Doripenem; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hospital Costs; Humans; Imipenem; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Ventilator-Associated; Survival Rate; Treatment Outcome | 2008 |
26 other study(ies) available for imipenem, anhydrous and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
[Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin, Imipenem Drug Combination; COVID-19; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; SARS-CoV-2 | 2022 |
Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Intensive Care Units; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Vietnam | 2017 |
Extended infusion versus intermittent infusion of imipenem in the treatment of ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cohort Studies; Drug Administration Schedule; Female; Humans; Imipenem; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Middle Aged; Pneumonia, Ventilator-Associated; Respiration, Artificial; Retrospective Studies; Time Factors; Treatment Outcome | 2017 |
Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Topics: beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Sensitivity and Specificity | 2018 |
Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactam Resistance; Critical Illness; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Imipenem; Intensive Care Units; Kaplan-Meier Estimate; Male; Multivariate Analysis; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Retrospective Studies; Risk Factors; RNA, Ribosomal, 16S; Tertiary Care Centers; Treatment Outcome | 2014 |
Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2015 |
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Load; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Treatment Outcome | 2015 |
Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Minocycline; Pneumonia, Ventilator-Associated; Prognosis; Retrospective Studies; Salvage Therapy; Survival Analysis; Tigecycline; Tunisia | 2015 |
Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of cl
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumonia, Ventilator-Associated; Salvage Therapy; Sulbactam; Taiwan; Tigecycline; Treatment Outcome | 2016 |
Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Female; Humans; Imipenem; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Shock, Septic | 2016 |
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins; Treatment Outcome | 2016 |
Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India.
Topics: Amikacin; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; India; Intensive Care Units; Klebsiella; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas; Staphylococcus aureus; Tertiary Care Centers; Vancomycin-Resistant Enterococci | 2016 |
Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2017 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Clinical and economic consequences of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Health Care Costs; Hospital Mortality; Humans; Imipenem; Intensive Care Units; Length of Stay; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Severity of Illness Index | 2009 |
Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cost-Benefit Analysis; Decision Support Techniques; Doripenem; Hospitalization; Humans; Imipenem; Intensive Care Units; Length of Stay; Middle Aged; Models, Economic; Monte Carlo Method; Pneumonia, Ventilator-Associated; Probability; Respiration, Artificial; Time Factors; United States | 2010 |
[A case of ventilator-associated pneumonia caused by Cupriavidus pauculus].
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cupriavidus; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Immunocompromised Host; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Respiratory Insufficiency; Ventilators, Mechanical | 2010 |
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2010 |
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Doripenem; Drug Combinations; Humans; Imipenem; Length of Stay; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Young Adult | 2010 |
Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tobramycin | 2010 |
Prevalence and clinical outcomes of episodes of ventilator-associated pneumonia caused by SPM-1-producing and non-producing imipenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Brazil; Female; Humans; Imipenem; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Doripenem: excess mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Early Termination of Clinical Trials; Evidence-Based Medicine; Humans; Imipenem; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Female; Humans; Imipenem; Male; Pneumonia, Ventilator-Associated | 2013 |
Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Case-Control Studies; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Male; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Retrospective Studies; Time Factors | 2007 |
Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Humans; Imipenem; Male; Nebulizers and Vaporizers; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography | 2008 |